Literature DB >> 21156226

Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.

Stephanie A Smoley1, Daniel L Van Dyke, Neil E Kay, Nyla A Heerema, Marie L Dell' Aquila, Paola Dal Cin, Prasad Koduru, Ayala Aviram, Laura Rassenti, John C Byrd, Kanti R Rai, Jennifer R Brown, Andrew W Greaves, Jeanette Eckel-Passow, Donna Neuberg, Thomas J Kipps, Gordon W Dewald.   

Abstract

Five laboratories in the Chronic Lymphocytic Leukemia (CLL) Research Consortium (CRC) investigated standardizing and pooling of fluorescence in situ hybridization (FISH) results as a collaborative research project. This investigation used fixed bone marrow and blood cells available from previous conventional cytogenetic or FISH studies in two pilot studies, a one-day workshop, and proficiency test. Multiple FISH probe strategies were used to detect 6q-, 11q-, +12, 13q-, 17p-, and IGH rearrangements. Ten specimens were studied by participants who used their own probes (pilot study 1). Of 312 FISH interpretations, 224 (72%) were true-negative, 74 (24%) true-positive, 6 (2%) false-negative, and 8 (3%) false-positive. In pilot study no. 2, each participant studied two specimens using identical FISH probe sets to control for variation due to probe sets and probe strategies. Of 80 FISH interpretations, no false interpretations were identified. At a subsequent workshop, discussions produced agreement on scoring criteria. The proficiency test that followed produced no false-negative results and 4% (3/68) false-positive interpretations. Interpretation disagreements among laboratories were primarily attributable to inadequate normal cutoffs, inconsistent scoring criteria, and the use of different FISH probe strategies. Collaborative organizations that use pooled FISH results may wish to impose more conservative empiric normal cutoff values or use an equivocal range between the normal cutoff and the abnormal reference range to eliminate false-positive interpretations. False-negative results will still occur, and would be expected in low-percentage positive cases; these would likely have less clinical significance than false positive results. Individual laboratories can help by closely following rigorous quality assurance guidelines to ensure accurate and consistent FISH studies in their clinical practice and research.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156226      PMCID: PMC3763815          DOI: 10.1016/j.cancergencyto.2010.08.009

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  15 in total

1.  A multicenter investigation with D-FISH BCR/ABL1 probes.

Authors:  G Dewald; R Stallard; A Alsaadi; S Arnold; R Blough; T M Ceperich; B Rafael Elejalde; J Fink; J V Higgins; R R Higgins; G A Hoeltge; W T Hsu; E B Johnson; D Kronberger; D J McCorquodale; L F Meisner; M A Micale; L Oseth; J S Payne; S Schwartz; S Sheldon; A Sophian; P Storto; P Van Tuinen; G D Wenger; A Wiktor; L A Willis; J F Yung; J Zenger-Hain
Journal:  Cancer Genet Cytogenet       Date:  2000-01-15

2.  A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia.

Authors:  Salil Goorha; Martha J Glenn; Elizabeth Drozd-Borysiuk; Zhong Chen
Journal:  Genet Med       Date:  2004 Jan-Feb       Impact factor: 8.822

3.  Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia.

Authors:  G W Dewald; W A Wyatt; A L Juneau; R O Carlson; A R Zinsmeister; S M Jalal; J L Spurbeck; R T Silver
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

4.  A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes.

Authors:  G Dewald; R Stallard; A Al Saadi; S Arnold; P I Bader; R Blough; K Chen; B R Elejalde; C J Harris; R R Higgins; G A Hoeltge; W T Hsu; V Kubic; D J McCorquodale; M A Micale; J W Moore; R M Phillips; S Scheib-Wixted; S Schwartz; S Siembieda; K Strole; P VanTuinen; G H Vance; A Wiktor; A Zinsmeister
Journal:  Am J Med Genet       Date:  1998-04-01

5.  Toward quality assurance for metaphase FISH: a multicenter experience.

Authors:  G W Dewald; R Stallard; P I Bader; K Chen; J Zenger-Hain; C J Harris; R Higgins; B Hirsch; W T Hsu; E Johnson; V Kubic; T W Kurczynski; J M Malone; D J McCorquodale; K Meilinger; L F Meisner; J W Moore; S Schwartz; S Siembieda; P D Storto; G Vance; P Van Tuinen; A Wiktor; J F Yung
Journal:  Am J Med Genet       Date:  1996-10-28

6.  Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.

Authors:  Stephanie R Fink; Sarah F Paternoster; Stephanie A Smoley; Heather C Flynn; Susan M Geyer; Tait D Shanafelt; You Kyoung Lee; Diane F Jelinek; Neil E Kay; Gordon W Dewald
Journal:  Leuk Res       Date:  2005-03       Impact factor: 3.156

7.  Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia.

Authors:  G S Nowakowski; G W Dewald; J D Hoyer; S F Paternoster; K J Stockero; S R Fink; S A Smoley; E D Remstein; R L Phyliky; T G Call; T D Shanafelt; N E Kay; C S Zent
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

8.  Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

Authors:  Gordon W Dewald; Terry Therneau; Dirk Larson; You Kyoung Lee; Stephanie Fink; Stephanie Smoley; Sarah Paternoster; Adewale Adeyinka; Rhett Ketterling; Daniel L Van Dyke; Rafael Fonseca; Robert Kyle
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

9.  Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.

Authors:  Gordon W Dewald; Stephanie R Brockman; Sarah F Paternoster; Nancy D Bone; Judith R O'Fallon; Cristine Allmer; Charles D James; Diane F Jelinek; Renee C Tschumper; Curtis A Hanson; Rajiv K Pruthi; Thomas E Witzig; Timothy G Call; Neil E Kay
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

10.  A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia.

Authors:  Daniel L Van Dyke; Tait D Shanafelt; Timothy G Call; Clive S Zent; Stephanie A Smoley; Kari G Rabe; Susan M Schwager; Jessica C Sonbert; Susan L Slager; Neil E Kay
Journal:  Br J Haematol       Date:  2009-11-06       Impact factor: 6.998

View more
  8 in total

1.  IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Authors:  Hong Fang; Kaaren K Reichard; Kari G Rabe; Curtis A Hanson; Timothy G Call; Wei Ding; Saad S Kenderian; Eli Muchtar; Susan M Schwager; Jose F Leis; Asher A Chanan-Khan; Susan L Slager; Esteban Braggio; Stephanie A Smoley; Neil E Kay; Tait D Shanafelt; Daniel L Van Dyke; Sameer A Parikh
Journal:  Am J Hematol       Date:  2019-01-08       Impact factor: 10.047

2.  Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

Authors:  Marc DE Braekeleer; Corine Tous; Nadia Guéganic; Marie-Josée LE Bris; Audrey Basinko; Frédéric Morel; Nathalie Douet-Guilbert
Journal:  Mol Clin Oncol       Date:  2016-02-26

Review 3.  Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.

Authors:  Sara Martinelli; Antonio Cuneo; Luca Formigaro; Maurizio Cavallari; Enrico Lista; Francesca Maria Quaglia; Maria Ciccone; Antonella Bardi; Eleonora Volta; Elisa Tammiso; Elena Saccenti; Olga Sofritti; Giulia Daghia; Massimo Negrini; Melissa Dabusti; Paolo Tomasi; Sabrina Moretti; Francesco Cavazzini; Gian Matteo Rigolin
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-15       Impact factor: 2.576

4.  PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.

Authors:  M A Gamaleldin; O M Ghallab; E A Nadwan; R A Abo Elwafa
Journal:  Clin Transl Oncol       Date:  2021-06-13       Impact factor: 3.405

5.  The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

Authors:  Daniel L Van Dyke; Lillian Werner; Laura Z Rassenti; Donna Neuberg; Emanuella Ghia; Nyla A Heerema; Paola Dal Cin; Marie Dell Aquila; Chandrika Sreekantaiah; Andrew W Greaves; Thomas J Kipps; Neil E Kay
Journal:  Br J Haematol       Date:  2016-02-05       Impact factor: 6.998

6.  Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.

Authors:  M J J Rose-Zerilli; J Gibson; J Wang; W Tapper; Z Davis; H Parker; M Larrayoz; H McCarthy; R Walewska; J Forster; A Gardiner; A J Steele; C Chelala; S Ennis; A Collins; C C Oakes; D G Oscier; J C Strefford
Journal:  Leukemia       Date:  2016-02-05       Impact factor: 11.528

Review 7.  Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.

Authors:  Tyler A Herek; Christine E Cutucache
Journal:  Front Oncol       Date:  2017-05-02       Impact factor: 6.244

8.  Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran.

Authors:  Hossein Rahimi; Mohammad Hadi Sadeghian; Mohammad Reza Keramati; Amir Hossein Jafarian; Sepideh Shakeri; Seyyede Fatemeh Shams; Neda Motamedi; Maryam Sheikhi; Hossein Ayatollahi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.